Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 12/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.78 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.78 |
| ▸ | PGR | P06401 | 2/20 | 0.78 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.78 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.78 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.78 |
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | GC | P02774 | 1/20 | 0.71 |
| ▸ | RXRA | P19793 | 1/20 | 0.71 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.71 |
| ▸ | CNR1 | P21554 | 1/20 | 0.71 |
| ▸ | HTR2C | P28335 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ercalcitriol SCHEMBL17274136 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL17274137 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL4393978 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL9050396 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL12922723 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL264876 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL4393975 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL301082 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL21433255 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR | |
| Ercalcitriol SCHEMBL8776000 | 1.00 | VDR (0.80) | VDRADORA3SLC6A2NR1I2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293551-A1 | USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4378483-A1 | USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-115078578-A | Serum vitamin D related metabolite detection method based on liquid chromatography-mass spectrometry | 广州市妇女儿童医疗中心 | 2022-09-20 | — | — | CN | disclosed |
| EP-4037690-A1 | COMBINED THERAPY COMPRISING AN INHIBITOR OF INTERLEUKIN-17 ACTIVITY AND A VITAMIN D RECEPTOR AGONIST | Servei de Salut de Les Illes Balears - Ibsalut (ES) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021063945-A1 | COMBINED THERAPY COMPRISING AN INHIBITOR OF INTERLEUKIN-17 ACTIVITY AND A VITAMIN D RECEPTOR AGONIST | SERVEI DE SALUT DE LES ILLES BALEARS – IBSALUT (ES) | 2021-04-08 | — | — | WO | disclosed |
| EP-3797779-A1 | COMBINED THERAPY COMPRISING AN INHIBITOR OF INTERLEUKIN-17 ACTIVITY AND A VITAMIN D RECEPTOR AGONIST | Servei de Salut de Les Illes Balears - Ibsalut (ES) | 2021-03-31 | — | — | EP | disclosed |
| CN-107382804-A | A kind of 1 α for preparing high-purity, the method for 25 dihydroxyvitamin Ds 2 | 南京海融医药科技股份有限公司 | 2017-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293551-A1 | USE OF ST-TYPE LIPID COMPOUNDS IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT | POLRMT, LIPC, POLM | VDR 1832/4885ADORA3 1585/4885SLC6A2 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.